Articles tagged with: BT-062
News»
Monday was the third day of this year’s meeting of the American Society of Hematology (ASH). The day was filled with oral presentation sessions from early in the morning until into the evening.
In the afternoon and early evening, there were six oral presentation sessions devoted solely to multiple myeloma and a number of other myeloma-related presentations scattered about the afternoon. The topics of these presentations ranged from the biology of myeloma to treatment options for newly diagnosed, relapsed and refractory, and older patients.
This ASH update highlights most of the oral …
News»
This article is the second in The Beacon’s ‘preview’ series about myeloma research that will be presented at the American Society of Hematology (ASH) meeting in early December.
Abstracts for the ASH presentations are now available; these abstracts contain preliminary data, and updated data will be presented at the meeting.
The Beacon's ASH preview articles, which will be published over the next couple of weeks, will highlight the most interesting myeloma-related studies that will be presented at the meeting.
The first preview, which was published last …
News»
In a recent review article published in the journal Clinical Cancer Research, two myeloma experts from the Dana-Farber Cancer Institute, Dr. Nikhil Munshi and Dr. Kenneth Anderson, review the latest strategies in the treatment of multiple myeloma.
In their article, the experts discuss newer therapies that appear to be promising in clinical and preclinical studies.
According to the physicians, combination therapies that specifically target a patient’s genetic form of the disease will be required for long-term disease control and ultimately a cure.
Some Historical Perspective
In their review article, Drs. Munshi and …
News»
Monday was the third and next-to-last day of the 2012 American Society of Hematology (ASH) annual meeting.
It also was the busiest day of the meeting in regard to myeloma-related research.
The day ended with a poster session in the evening that featured over 1000 posters displayed throughout a large conference hall. More than a hundred of the posters reported on the results of myeloma-related research.
Compared to the research summarized during oral presentations, the findings in poster summaries generally are in earlier stages of development. They may involve laboratory research, clinical …
NewsFlash »
Biotest AG Starts Clinical Trial Of BT-062 Combination Therapy – The German pharmaceutical company Biotest AG has begun a Phase 1/2 clinical trial of BT-062 in combination with Revlimid (lenalidomide) and dexamethasone (Decadron) in patients with relapsed and/or refractory multiple myeloma. BT-062 consists of a chemotherapeutic drug combined with an antibody that helps deliver the drug to myeloma and other cancer cells. BT-062 alone has demonstrated anti-myeloma activity and good tolerability in relapsed and refractory myeloma patients. Furthermore, preclinical studies have shown BT-062 to be more effective when combined with Revlimid. For more information, please see the Biotest AG press release and the clinical trial description.
Kyprolis And Oprozomib May Decrease Bone Damage In Multiple Myeloma – The results of a preclinical study suggest that Kyprolis (carfilzomib) and oprozomib may prevent bone loss in multiple myeloma. Kyprolis and oprozomib are both being developed by Onyx Pharmaceuticals, and both belong to the same class of drugs as Velcade (bortezomib), known as proteasome inhibitors. Kyprolis was approved last week by the U.S. Food and Drug Administration for the treatment of people with multiple myeloma who have received at least two prior therapies (see related Beacon news). Oprozomib, which will be administered orally, is still in the early clinical development phase. In this study, researchers found that carfilzomib and oprozomib enhanced bone formation and decreased bone destruction in healthy mice. Additionally, in mice with multiple myeloma, treatment with carfilzomib or oprozomib resulted in a smaller tumor burden and prevented bone destruction. For more information, please see the study in Leukemia (abstract).
NDC May Overcome Multidrug Resistance And Prevent Doxorubicin-Induced Heart Disease In Myeloma Patients – The results of a recent preclinical study show that a doxorubicin-curcumin compound called NanoDoxCurc (NDC) may overcome resistance to doxorubicin (Adriamycin) while preventing treatment-related heart disease. Doxorubicin is a common anticancer agent that becomes less effective in cancer cells demonstrating multidrug resistance. In higher doses, doxorubicin can overcome multidrug resistance, but is also associated with heart disease. In this study, NDC-treated mice with multiple myeloma demonstrated lower tumor burdens than mice treated with doxorubicin alone. Furthermore, mice treated with NDC did not experience heart complications. The study investigators believe these findings indicate that NDC may be a safe and long-lasting cancer therapy. For more information, please see the study in Oncotarget.
BCMA Levels May Be A Disease Marker In Multiple Myeloma – In a recent study, researchers found that B-cell maturation antigen (BCMA) levels in the blood are elevated in multiple myeloma patients and are associated with disease status and overall survival. BCMAs can be found on the surface of both normal and cancerous B-cells, a type of white blood cell. In the current study, BCMA levels in the blood were higher in multiple myeloma patients compared to those in healthy adults. Furthermore, patients with progressive disease demonstrated higher BCMA levels than those who were responsive to treatment. After a median follow-up time of 11 months, patients with BCMA levels above the median had shorter overall survival times than patients below the median. For more information, please see the study in the British Journal of Haematology (abstract).
News»
The results of a small Phase 1 clinical trial demonstrate that BT-062, a new drug specifically targeting multiple myeloma cells, shows activity and is tolerable in heavily pretreated multiple myeloma patients.
Dr. Sundar Jagannath of the Mount Sinai Medical Center in New York City presented the results at the 2011 American Society of Hematology (ASH) conference in San Diego last month.
Based on the favorable safety and activity of BT-062, a Phase 1/2 clinical trial has been initiated and is currently recruiting patients. It will use a more frequent dosing …
News»
Yesterday was the third day of the American Society of Hematology (ASH) 2011 Annual Meeting in San Diego, and it was packed full with multiple myeloma-related presentations. Presentations started early in the morning and continued through the afternoon.
The morning presentations about potential new myeloma therapies will be covered in this update, and presentations from the rest of the day will be covered in additional updates.
MLN9708
During the first talk of the day, Dr. Paul Richardson from the Dana-Farber Cancer Institute in Boston presented results from a Phase 1 study of …
